Zimvie

Zimvie, Inc. operates as a holding company, which engages in the manufacture, design, and distribution of medical devices and surgical instruments. It operates through the Spine Products and Dental Products segments. The Spine Products segment offers spinal surgery solutions such as implants, instrumentation, biologics, and bone healing technologies to treat patients with back or neck pain caused by degenerative conditions, deformities, tumors or traumatic injury of the spine. The Dental Products segment provides dental implant solutions, biomaterial solutions, and digital dentistry. The company was founded on November 4, 2021 and is headquartered in Westminster, CO.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

ZIMV reports mixed Q1 performance, raises full-year guidance

ZIMV's Q1 2023 performance showed mixed results, with improvements in gross margin but a decline in adjusted EBITDA. However, upward revisions in net sales and earnings guidance reflect confidence in future prospects. Challenges in the spine segment and investor inquiries highlight areas of concern, while opportunities lie in innovation and customer support.

ZimVie reports mixed Q2 performance, sees opportunities in collaborations

ZimVie's Q2 2023 performance showed growth in dental net sales but a decline in spine net sales. The company's strength in innovation and commercial execution is evident, but challenges exist in the spine segment and expanding EBITDA margins. Despite challenges, ZimVie sees opportunities in collaborations and remains confident in its portfolio's ability to deliver results.

ZIMV reports strong Q3 performance and eyes spine market talent acquisition

ZIMV's Q3 2023 earnings call highlighted strong financial performance, progress in innovation, and a positive outlook for the full year. The company's confidence in its position and potential talent acquisition in the spine market signals a promising future amidst market challenges and opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

PALM BEACH GARDENS, Fla., April 24, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental market, today announced it will report financial results for the first quarter 2024 after market close on Wednesday, May 8, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report First Quarter Financial Results on May 8, 2024

Completion of Sale to an Affiliate of H.I.G. Capital for $375 Million Establishes Pure-Play Dental Business Completion of Sale to an Affiliate of H.I.G. Capital for $375 Million Establishes Pure-Play Dental Business

ZimVie Announces Closing of Sale of Spine Business

MIAMI--(BUSINESS WIRE)-- #Acquisition--H.I.G. Capital completed the acquisition of the Spine division of ZimVie, Inc., renamed Highridge Medical.

H.I.G. Capital Acquires the Spine Business of ZimVie Rebranded as Highridge Medical

WESTMINSTER, Colo., March 27, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced management will participate in the upcoming 23rd Annual Needham Virtual Healthcare Conference. Management will be presenting on Wednesday, April 10th, 2024 at 3:00 p.m. Eastern Time / 12:00 p.m. Pacific Time.

ZimVie to Participate in the 23rd Annual Needham Virtual Healthcare Conference

ZimVie Inc. (ZIMV) Q4 2023 Earnings Call Transcript

WESTMINSTER, Colo., Feb. 21, 2024 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the fourth quarter and full-year 2023 after market close on Wednesday, February 28, 2024. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Fourth Quarter and Full-Year 2023 Financial Results on February 28, 2024

Newest implant innovation is designed for immediacy and peri-implant health Newest implant innovation is designed for immediacy and peri-implant health

ZimVie Announces Launch of Next-Generation TSX® Implant in Japan

ZimVie's stock has doubled since reporting Q3 earnings, causing investors to wonder about the company's future. The company's Q3 revenues declined less than expected and the company raised full-year guidance. More importantly, ZimVie's decision to sell its spine business for $375 million jettisons an underperforming segment while solving a debt overhang.

ZimVie: Focusing On Higher Growth Dental Business (Rating Upgrade)

ZimVie Inc. (NASDAQ:ZIMV ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Richard Heppenstall - Chief Financial Officer Conference Call Participants Lilly Wyttenbach - JPMorgan Matt Miksic - Barclays Operator Good day, and thank you for standing by. Welcome to the ZimVie Third Quarter 2023 Financial Results Conference Call.

ZimVie Inc. (ZIMV) Q3 2023 Earnings Call Transcript

WESTMINSTER, Colo., Oct. 31, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that the first patient in the United States has received the newly approved 4.5mm Mobi-C® Cervical Disc. Introduced in France in 2004, Mobi-C became the first cervical disc approved for one and two levels by the FDA in 2013. The smaller 4.5mm height Mobi-C implants, available in seven footprints to match patient anatomy, were approved by the FDA in August of this year.

ZimVie Announces First U.S. Surgery with the 4.5mm Mobi-C® Cervical Disc

Cano Health

Carter's

Sunstone Hotel Investors

Virgin Galactic

Service Properties Trust

Territorial Bancorp

While it's an uncomfortable topic, every investor must face the prospect of stocks to sell. Like it or not, market success doesn't just come down to picking winners.

Brace for Impact: 7 Stocks to Sell Amid Rising Troubles

New offerings expand ZimVie's dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio New offerings expand ZimVie's dental solutions for lab customers, enhancing selection and broadening the reach of the ZimVie portfolio

ZimVie Announces the Launch of Azure™ Multi-Platform Product Solutions

ZimVie's (ZIMV) Biotivity A/C Plus Membrane is a barrier membrane that contains an array of growth factors.

ZimVie (ZIMV) Progresses in Dental Space With Biotivity Launch

WESTMINSTER, Colo., Oct. 11, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the third quarter 2023 after market close on Wednesday, November 1, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Third Quarter 2023 Financial Results on November 1, 2023

New offering broadens ZimVie's dental portfolio into the expanding growth factor biomaterials market New offering broadens ZimVie's dental portfolio into the expanding growth factor biomaterials market

ZimVie Announces the Recent Launch of Biotivity™ A/C Plus Membrane

Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion Decision clears the way for enrollment of U.S. patients in a groundbreaking clinical study of cervical arthroplasty adjacent to fusion

ZimVie Announces FDA Approval to Launch Mobi-C® Hybrid Study

ZimVie and Brainlab will cooperate on achieving compatibility between ZimVie's Vital™ and Virage ® fixation systems with the Brainlab spine and trauma technologies for global co-marketing purposes

ZimVie Expands Development Cooperation Agreement with Brainlab AG to Include Co-Marketing

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, ZimVie Inc. (ZIMV) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Why Fast-paced Mover ZimVie Inc. (ZIMV) Is a Great Choice for Value Investors

ZimVie Inc. (NASDAQ:ZIMV ) Q2 2023 Earnings Conference Call August 2, 2023 4:30 PM ET Company Participants Marissa Bych - Investor Relations, Gilmartin Group LLC Vafa Jamali - President and Chief Executive Officer Rich Heppenstall - Chief Financial Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Matt Miksic - Barclays Operator Good afternoon, and welcome to ZimVie's Second Quarter 2023 Earnings Conference Call. Currently, all participants are in listen-only mode.

ZimVie Inc. (ZIMV) Q2 2023 Earnings Call Transcript

ZimVie Inc. (ZIMV) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.67 per share a year ago.

ZimVie Inc. (ZIMV) Tops Q2 Earnings and Revenue Estimates

WESTMINSTER, Colo., Aug. 02, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today reported financial results for the second quarter ended June 30, 2023. Management will host a corresponding conference call today, August 2, 2023, at 4:30 p.m. Eastern Time.

ZimVie Reports Second Quarter 2023 Financial Results and Provides Update to Annual Guidance

ZimVie Inc. (ZIMV) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

ZimVie Inc. (ZIMV) Stock Jumps 20.6%: Will It Continue to Soar?

WESTMINSTER, Colo., July 12, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023. Company management will host a corresponding conference call beginning at 4:30 p.m. Eastern Time.

ZimVie to Report Second Quarter 2023 Financial Results on August 2, 2023

ZimVie's stock price has increased by 19% since November, but the company's fundamentals have deteriorated significantly. The company's revenue guidance for 2023 is set at $848 million, a 6.7% decline from 2022, and LTM CFO has been cut in half from $55 million in Q3/22 to $27 million in Q1/23. With deteriorating fundamentals and higher valuations, I lower the rating on ZIMV to a hold and advise investors to wait for better valuations before considering a position in the company.

ZimVie: Downgrade To A Hold On Valuation And Fundamentals

WESTMINSTER, Colo., May 22, 2023 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that the company will be participating in the upcoming Stifel 2023 Jaws & Paws Conference in New York. Management will be hosting a presentation on Wednesday, May 31st, 2023, at 12:40 p.m. Eastern Time / 9:40 a.m. Pacific Time. Stifel's Jaws & Paws is a leading conference in the Dental and Animal Health industries.

News for Zimvie Stock (ZIMV)